| Kevin J Kerwin, MD | |
|
18200 Lorain Ave, Cleveland, OH 44111-5605 | |
| (216) 476-7606 | |
| (216) 476-6967 |
| Full Name | Kevin J Kerwin |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 27 Years |
| Location | 18200 Lorain Ave, Cleveland, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740233469 | NPI | - | NPPES |
| 2411607 | Medicaid | OH | |
| 000000369933 | Other | OH | ANTHEM BC/BS |
| 349937 | Other | OH | WELLCARE |
| P00337656 | Other | OH | RAILROAD CARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 35083010 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fairview Hospital | Cleveland, OH | Hospital |
| Cleveland Clinic | Cleveland, OH | Hospital |
| Cleveland Clinic Avon Hospital | Avon, OH | Hospital |
| Lutheran Hospital | Cleveland, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cleveland Clinic Foundation | 1850203555 | 5690 |
News Archive
During a town hall meeting Tuesday on health care reform, Senator Arlen Specter (D-Pa.) stated his opposition to legislation that would cover illegal aliens. Specter has been a long-time champion of amnesty for illegal aliens, he was the author of the 2006 amnesty bill (S. 2611) that was widely rejected by the American people.
EpiCept Corporation today announced that the National Cancer Institute (NCI) has initiated a Phase II trial with crolibulinTM (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with anaplastic thyroid cancer (ATC). CrolibulinTM is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.
Researchers around the world have tried many ways, and for many years, to generate neurons in the lab so they could study them better. Neurons-on-demand might also provide a therapeutic option for replacing neurons lost in neurodegenerative conditions, such as Parkinson's disease.
Shire plc announced today it has entered into an agreement with Sanquin Blood Supply, the manufacturer of CINRYZE (C1 esterase inhibitor [human]), providing Shire access to its manufacturing technology and allowing Shire to source additional manufacturers to meet the growing demand for CINRYZE.
› Verified 3 days ago
| Entity Name | The Cleveland Clinic Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679525919 PECOS PAC ID: 1850203555 Enrollment ID: O20031103000049 |
News Archive
During a town hall meeting Tuesday on health care reform, Senator Arlen Specter (D-Pa.) stated his opposition to legislation that would cover illegal aliens. Specter has been a long-time champion of amnesty for illegal aliens, he was the author of the 2006 amnesty bill (S. 2611) that was widely rejected by the American people.
EpiCept Corporation today announced that the National Cancer Institute (NCI) has initiated a Phase II trial with crolibulinTM (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with anaplastic thyroid cancer (ATC). CrolibulinTM is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.
Researchers around the world have tried many ways, and for many years, to generate neurons in the lab so they could study them better. Neurons-on-demand might also provide a therapeutic option for replacing neurons lost in neurodegenerative conditions, such as Parkinson's disease.
Shire plc announced today it has entered into an agreement with Sanquin Blood Supply, the manufacturer of CINRYZE (C1 esterase inhibitor [human]), providing Shire access to its manufacturing technology and allowing Shire to source additional manufacturers to meet the growing demand for CINRYZE.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kevin J Kerwin, MD 18200 Lorain Ave, Cleveland, OH 44111-5605 Ph: (216) 476-7606 | Kevin J Kerwin, MD 18200 Lorain Ave, Cleveland, OH 44111-5605 Ph: (216) 476-7606 |
News Archive
During a town hall meeting Tuesday on health care reform, Senator Arlen Specter (D-Pa.) stated his opposition to legislation that would cover illegal aliens. Specter has been a long-time champion of amnesty for illegal aliens, he was the author of the 2006 amnesty bill (S. 2611) that was widely rejected by the American people.
EpiCept Corporation today announced that the National Cancer Institute (NCI) has initiated a Phase II trial with crolibulinTM (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with anaplastic thyroid cancer (ATC). CrolibulinTM is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.
Researchers around the world have tried many ways, and for many years, to generate neurons in the lab so they could study them better. Neurons-on-demand might also provide a therapeutic option for replacing neurons lost in neurodegenerative conditions, such as Parkinson's disease.
Shire plc announced today it has entered into an agreement with Sanquin Blood Supply, the manufacturer of CINRYZE (C1 esterase inhibitor [human]), providing Shire access to its manufacturing technology and allowing Shire to source additional manufacturers to meet the growing demand for CINRYZE.
› Verified 3 days ago
Amir Razavi, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Dr. Francois Fadell, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 18200 Lorain Ave, Moll Cancer Center At Fairview- Respiratory Institute, Cleveland, OH 44111 Phone: 216-444-6503 | |
Sana Hasan, DO Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195 Phone: 330-721-5700 | |
Catherine Frakes Vozzo, DO Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 9500 Euclid Ave, Cleveland, OH 44195 Phone: 216-444-4444 Fax: 216-445-6290 | |
Tarek Ashour, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave # Q7, Cleveland, OH 44195 Phone: 216-444-5040 | |
Mrs. Efewongbe Benedicta Oleghe, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2351 E 22nd Street, St Vincent's Charity Medical Center, Cleveland, OH 44115 Phone: 216-363-2725 | |
Dr. Toufik Z. Madhun, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 11100 Euclid Ave Dept Of, Cleveland, OH 44106 Phone: 216-844-1000 |